About creative medical technology holdings inc - CELZ
Creative Medical Technology Holdings, Inc. is a commercial stage biotechnology company which focuses on immunology, urology, neurology and orthopedics using adult stem cell treatments and interrelated regenerative technologies for the treatment of multiple indications. Its products include CaverStem, FemCelz, StemSpine and ImmCelz. The company was founded on December 3, 1998 and is headquartered in Phoenix, AZ.
CELZ At a Glance
Creative Medical Technology Holdings, Inc.
211 East Osborn Road
Phoenix, Arizona 85012
| Phone | 1-833-336-7636 | Revenue | 11.00K | |
| Industry | Medical Specialties | Net Income | -5,493,481.00 | |
| Sector | Health Technology | 2024 Sales Growth | 22.222% | |
| Fiscal Year-end | 12 / 2025 | Employees | 4 | |
| View SEC Filings |
CELZ Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 310.888 |
| Price to Book Ratio | 0.637 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | 0.447 |
| Enterprise Value to Sales | -229.148 |
| Total Debt to Enterprise Value | N/A |
CELZ Efficiency
| Revenue/Employee | 2,750.00 |
| Income Per Employee | -1,373,370.25 |
| Receivables Turnover | N/A |
| Total Asset Turnover | 0.001 |
CELZ Liquidity
| Current Ratio | 18.726 |
| Quick Ratio | 18.719 |
| Cash Ratio | 18.131 |
CELZ Profitability
| Gross Margin | -944.109 |
| Operating Margin | -52,216.909 |
| Pretax Margin | -49,940.736 |
| Net Margin | -49,940.736 |
| Return on Assets | -63.20 |
| Return on Equity | -65.848 |
| Return on Total Capital | -86.627 |
| Return on Invested Capital | -65.848 |
CELZ Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | N/A |
| Total Debt to Total Assets | N/A |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | N/A |